DeepMed Research

INVICRO

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain

Early Phase 1

Completed

Conditions: Alpha-Synucleinopathy
Parkinson's Disease
Dementia With Lewy Bodies
Multisystem Atrophy

Interventions: Drug: [18F]MNI-1216

First Posted Date: 2024-06-06

Last Posted Date: 2025-02-19

Lead Sponsor: Invicro

Target Recruit Count: 12

Registration Number: NCT06445465

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein

Phase 1

Completed

Conditions: Parkinson Disease
Multisystem Atrophy
Healthy Volunteer

Interventions: Drug: [18F]UCB-2897

First Posted Date: 2022-03-10

Last Posted Date: 2025-02-20

Lead Sponsor: Invicro

Target Recruit Count: 5

Registration Number: NCT05274568

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Amyvid

First Posted Date: 2021-12-20

Last Posted Date: 2025-02-28

Lead Sponsor: Invicro

Target Recruit Count: 140

Registration Number: NCT05164536

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: [18F]MNI-444

First Posted Date: 2021-08-17

Last Posted Date: 2022-07-05

Lead Sponsor: Invicro

Target Recruit Count: 3

Registration Number: NCT05009199

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Evaluation of [18F]APN-1607 as a PET Biomarker

Phase 1

Completed

Conditions: Progressive Supranuclear Palsy
Healthy Volunteers

Interventions: Drug: [18F] APN-1607

First Posted Date: 2021-08-16

Last Posted Date: 2025-02-20

Lead Sponsor: Invicro

Target Recruit Count: 12

Registration Number: NCT05005819

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Assessment of the Biodistribution and Safety of [18F]MNI-1054

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [18F]MNI-1054

First Posted Date: 2018-10-25

Last Posted Date: 2019-05-23

Lead Sponsor: Invicro

Target Recruit Count: 4

Registration Number: NCT03719482

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Assessment of [18F]MNI-1054 as a Marker for LSD1

Early Phase 1

Completed

Conditions: Healthy Volunteers (HV)

Interventions: Drug: [18F]MNI-1054

First Posted Date: 2018-10-04

Last Posted Date: 2019-05-23

Lead Sponsor: Invicro

Target Recruit Count: 4

Registration Number: NCT03695926

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

Early Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: PF-06412562

First Posted Date: 2018-09-27

Last Posted Date: 2019-04-22

Lead Sponsor: Invicro

Target Recruit Count: 6

Registration Number: NCT03686501

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

Phase 1

Completed

Conditions: Healthy Volunteers
Parkinson Disease
Alzheimer Disease

Interventions: Drug: [18F]MNI-1126

First Posted Date: 2018-07-16

Last Posted Date: 2020-04-15

Lead Sponsor: Invicro

Target Recruit Count: 12

Registration Number: NCT03587649

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

Phase 1

Completed

Conditions: Healthy Volunteers
Alzheimer Disease
Progressive Supranuclear Palsy

Interventions: Drug: [18F]MNI-958

First Posted Date: 2018-06-04

Last Posted Date: 2020-02-17

Lead Sponsor: Invicro

Target Recruit Count: 16

Registration Number: NCT03545789

Locations: 🇺🇸
Invicro, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy